- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, doxorubicin hydrochloride / Generic mfg.
Journal, Combination therapy: Can Denosumab be used in combination with Doxorubicin in Osteosarcoma? (Pubmed Central) - Aug 1, 2020
These results indicate that the presence of Denosumab might inhibit the efficacy of the chemotherapic drug. In conclusion, while our results certainly support and confirm the efficacy of Denosumab in Osteoporosis, we discourage the use of Denosumab in addition to conventional chemotherapy in Osteosarcoma, even though, certainly further investigations are necessary to better clarify the clinical role of this monoclonal antibody in cancer.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, risedronate / Generic mfg., Bonrise (ibandronate sodium) / Elder Pharma
Clinical, Retrospective data, Journal: Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures: A Network Meta-Analysis. (Pubmed Central) - Jul 29, 2020
This difference was more pronounced in the first 12 months of BTA treatment.In mCRPC, strategies of BTA schedule de-escalation may take into account presence of extraskeletal metastases. In terms of clinical efficacy and safety, second-line teriparatide and denosumab pose a challenge to first-line oral bisphosphonates for prevention of GI fractures.
- |||||||||| Xofigo (radium Ra-223 dichloride) / Bayer
Clinical, Journal: Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223? (Pubmed Central) - Jul 29, 2020
The data from ERA 223 demonstrated no increase in efficacy for this combination over AAP alone, and instead identified a significant safety concern due to the higher risk of fracture in the co-treatment group. The surprising results of this trial likely stem from the compounding osteoporotic effects of the different treatments, particularly the addition of prednisone, and supplementing therapy regimens with osteoprotective agents may aid in mitigating this safety risk.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, risedronate / Generic mfg.
Journal: Effect of risedronate on bone loss at discontinuation of denosumab. (Pubmed Central) - Jul 28, 2020
The mean densitometric loss during the off-denosumab period was lower in patients with previous bisphosphonate exposure than in naïve patients (p = .043) and in patients with previous exposure to teriparatide (p = .05). Three months of risedronate treatment does not prevent bone loss in patients who have not been treated with bisphosphonates before denosumab.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
Clinical, Journal: Two Cases of Stage Ⅳ Occult Breast Cancer (Pubmed Central) - Jul 24, 2020
However, after 6 months, she discontinued the treatment. Our results suggested that effective control could be achieved through systemic therapy and local therapy was not necessary for Stage Ⅳ occult breast cancer.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: The Official Positions of the International Society for Clinical Densitometry: Detection of Atypical Femur Fractures. (Pubmed Central) - Jul 21, 2020
The ISCD recommends considering the use of bilateral FFI in patients who are currently or have been in the past year on potent antiresorptive therapy (ie, oral or intravenous bisphosphonate or subcutaneous denosumab therapy) for a cumulative period of 3 or more years, especially those on long-term glucocorticoid therapy (grade: Fair, B, W). More research is needed to determine the role of repeat testing and the optimal time interval for follow-up DXA scans, whether an automated measuring tool would perform better than visual inspection, whether FFI would change patient management and outcomes, and the cost-effectiveness of FFI.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: Dual-Energy X-Ray Absorptiometry Monitoring With Trabecular Bone Score: The 2019 ISCD Official Positions. (Pubmed Central) - Jul 21, 2020
TBS does not appear to be clinically useful to monitor the skeletal effects of bisphosphonates and denosumab, but is potentially useful as a component of monitoring the skeletal effects of teriparatide and abaloparatide...A significant decrease of TBS may represent a worsening of trabecular structure, suggesting the need for further clinical assessment and possible change in treatment strategies. Since BMD measures bone quantity and TBS measures bone quality, these tests can be considered complementary in assessing fracture risk and response to therapy in appropriate patients.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. (Pubmed Central) - Jul 21, 2020
Since BMD measures bone quantity and TBS measures bone quality, these tests can be considered complementary in assessing fracture risk and response to therapy in appropriate patients. In postmenopausal women with low bone mass noggin levels were not correlated with bone parameters at any time point, except with P1NP at 12 months, and remained stable with both denosumab and teriparatide treatment.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Denosumab-Associated Peri-Implant Atypical Femur Fracture: A Case Report. (Pubmed Central) - Jul 21, 2020
Bisphosphonate use has been associated with atypical pathologic fracture and slowed bone turnover. We present a case of a bisphosphonate-associated peri-implant atypical femur fracture following use of a recon nail for treatment of a prior bisphosphonate-associated atypical femur fracture.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Bone Tumors: Metastatic Bone Disease. (Pubmed Central) - Jul 21, 2020
Drugs to promote bone health (eg, bisphosphonates, denosumab) should be considered for all patients with metastatic disease. (This is an off-label use of some bisphosphonates.) When appropriate, palliative care is indicated.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, cinacalcet HCl / Generic mfg.
Clinical, P3 data, Clinical Trial,Phase III, Journal: Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. (Pubmed Central) - Jul 19, 2020
P3
(This is an off-label use of some bisphosphonates.) When appropriate, palliative care is indicated. Evidence suggested denosumab was effective in improving BMD and lowering bone turnover in patients with primary hyperparathyroidism irrespective of cinacalcet treatment and might be a valid option for patients in which surgery is undesirable.
- |||||||||| Strensiq (asfotase alfa) / Alexion Pharma, Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Review, Journal: Hypophosphatasia: Current Literature for Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment. (Pubmed Central) - Jul 19, 2020
The primary treatment for HPP is the reintroduction of TNAP as a recombinant enzyme called asfotase alfa...Pharmaceutical therapies such as bisphosphonates, denosumab, potent antiresorptive agents, and vitamin D are contraindicated in adults with HPP...We plan to encourage appropriate care and avoid treatments that may be contraindicating. We also encourage the development of a diagnostic guideline that will promote a consistently favorable patient prognosis.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. (Pubmed Central) - Jul 19, 2020
There was no significant difference between the denosumab and teriparatide groups at 24 months in lumbar spine and femoral neck BMD, but was significantly higher in the teriparatide group at 12 months (P < 0.01 and P < 0.05 in the lumbar spine and femoral neck, respectively). Teriparatide might have some advantages over denosumab and be a good alternative for treating GIO patients with prior bisphosphonate treatment.
- |||||||||| Retrospective data, Journal: Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). (Pubmed Central) - Jul 16, 2020
Meanwhile, there is no statistical difference between abaloparatide, teriparatide or romosozumab, and placebo in terms of safety. Furthermore, in terms of adverse events, zoledronic acid is statistically worse than placebo, and two of the best interventions are denosumab and romosozumab, of which denosumab also reduces the risk of different kinds of fractures.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Adjuvant denosumab in early breast cancer. (Pubmed Central) - Jul 16, 2020
The 'Cancer Treatment at Home' service has improved the patient experience for cancer care and has been recognized nationally for its achievements. No abstract available
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Trial completion date: Effect of Denosumab in Erosion Healing in RA (clinicaltrials.gov) - Jul 15, 2020
P2, N=110, Completed,
No abstract available Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> May 2020
- |||||||||| bortezomib / Generic mfg., Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
[VIRTUAL] Bone Diseases and Supportive Care () - Jul 14, 2020 - Abstract #SOHO2020SOHO_71;
Therefore, local interventions like vertebroplasty and kyphoplasty as well as radiation or in severe cases, surgery can be indicated.17 Comparison of the different techniques has shown a reduction in pain and disability, with a slight benefit for kyphoplasty over the other interventions.18 Conclusion Bone disease with an overactivation of osteoclasts and an inhibition of osteoblasts plays a significant role in not only the pathophysiology but also in the clinical handling of myeloma patients. It is, therefore, important to detect changes in the skeleton early, to treat them sufficiently, and to offer local and systemic interventions to repair damage that has already occurred.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evenity (romosozumab) / Astellas, Amgen, UCB
Journal: One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. (Pubmed Central) - Jul 11, 2020
It is, therefore, important to detect changes in the skeleton early, to treat them sufficiently, and to offer local and systemic interventions to repair damage that has already occurred. The sequence of romosozumab followed by denosumab may be a promising regimen for the treatment of osteoporosis.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
Journal: Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report. (Pubmed Central) - Jul 10, 2020
Routine radiographic screening for AFF might be necessary in patients with prolonged BMA use for bone metastasis, even if asymptomatic. This report alerts all physicians and surgeons involved in the management of cancer patients, especially those with bone metastasis, regarding the risk of AFF following BMA use.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date: Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis (clinicaltrials.gov) - Jul 10, 2020
P4, N=60, Active, not recruiting,
This report alerts all physicians and surgeons involved in the management of cancer patients, especially those with bone metastasis, regarding the risk of AFF following BMA use. Trial completion date: Dec 2020 --> Sep 2020
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Glucocorticoid induced osteoporosis. (Pubmed Central) - Jul 7, 2020
However, a number of alternative treatment options, including intravenous bisphosphonates, anabolic agents, and denosumab have all proven efficacy in increasing lumbar spine or hip bone mineral density...492 articles were found and 45 were included. Expert opinion: Future studies will likely evaluate the safety profiles of alternative treatments, while focusing on its ability to reduce fracture risk.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
Journal: Treatment options for glucocorticoid-induced osteoporosis. (Pubmed Central) - Jul 7, 2020
Moreover, while oral bisphosphonates remain the most used and cost-effective option, the potential increased benefits of more potent antiresorptive agents (e.g. denosumab and zoledronate) or anabolic compounds (e.g. teriparatide) warrant further investigation. Despite the above limitations, the assessment of fracture risk is recommended for all individuals committed to receiving oral GCs for 3 months or longer.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] Denosumab-Related Mononeuritis Leading to Diaphragm and Long Thoracic Nerve Paralysis (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_7533;
Interestingly, RANKL is present in endothelial cells and lymphocytes, suggesting a possible mechanism for immune-system-mediated neurological pathology. As the use of monoclonal antibodies increases, physicians should be aware of possible neurological complications.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
Journal: Endocrinology in the time of COVID-19: Management of calcium disorders and osteoporosis. (Pubmed Central) - Jul 3, 2020
Patients established on denosumab and teriparatide should continue planned therapy. The challenge of this pandemic will act as a catalyst to innovate within our management of metabolic bone and mineral disorders to ensure best use of resources and resilience of healthcare systems in its aftermath.
|
